References
- Nabel EG. (2003). Cardiovascular disease. N Engl J Med, 349:60–72.
- Available at: http://www.who.int/mediacentre/factsheets/fs317/en/index.html. Accessed on: June 2011.
- Criscione L, de Gasparo M, Bühlmayer P, Whitebread S, Ramjoué HP, Wood J. (1993). Pharmacological profile of valsartan: A potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol, 110:761–771.
- Dina R, Jafari M. (2000). Angiotensin II-receptor antagonists: An overview. Am J Health Syst Pharm, 57:1231–1241.
- Ripley TL. (2005). Valsartan in chronic heart failure. Ann Pharmacother, 39:460–469.
- Sweetman SC, ed. (2011). Martindale: The complete drug reference. London: Pharmaceutical Press. Available at: www.medicinescomplete.com. Accessed on: June 2011.
- Pfeffer-Hennig S, Piechon P, Bellus M, Goldbronn C, Tedesco E. (2004). Physico-chemical characterization of an active pharmaceutical ingredient: Crystal polyorphism and structrual analysis. J Therm Anal Calor, 77:663–679.
- Bond L, Allen S, Davies MC, Roberts CJ, Shivji AP, Tendler SJ et al. (2002). Differential scanning calorimetry and scanning thermal microscopy analysis of pharmaceutical materials. Int J Pharm, 243:71–82.
- Craig DQM, Reading M. (2006). Thermal analysis of pharmaceuticals. 1st ed. New York: CRC Press.
- Bynum KC. (2011). Preformulation and early phase method development. In: Ahuja S, Scypinski S, eds. Handbook of Modern Pharmaceutical Analysis (Separation Science and Technology). 2nd ed. Waltham: Academic Press, 361–396.
- Niazi SK. (2007). The scope of preformulation studies. In: Niazi SK, ed. Handbook of Preformulation Chemical, Biological, and Botanical Drugs. 1st ed. New York: Informa Healthcare, 57–86.
- Ibrahim HK, El-Setouhy DA. (2010). Valsartan orodispersible tablets: Formulation, in vitro/in vivo characterization. AAPS PharmSciTech, 11:189–196.
- Shrivastava AR, Ursekar B, Kapadia CJ. (2009). Design, optimization, preparation and evaluation of dispersion granules of valsartan and formulation into tablets. Curr Drug Deliv, 6:28–37.
- Wunderlich B. (2005). Thermal analysis of polymeric materials. Berlin: Springer-Verlag.
- Hu X, Lu Q, Kaplan DL, Cebe P. (2009). Microphase separation controlled β-sheet crystallization kinetics in fibrous proteins. Macromolecules, 42:2079–2087.
- Richardson MJ, Savill NG. (1975). Derivation of accurate glass-transition temperatures by differential scanning calorimetry. Polymer, 16:753–757.
- Hutchinson JM. (2009). Determination of the glass transition temperature: Methods correlation and structural heterogeneity. J Therm Anal Calorim, 98:579–589.
- Cowie JMG, Ferguson R. (1989). Physical aging studies in poly(vinyl methyl ether). 1. Enthalpy relaxation as a function of aging temperature. Macromolecules, 22:2307–2312.
- Airaksinen S, Karjalainen M, Shevchenko A, Westermarck S, Leppänen E, Rantanen J et al. (2005). Role of water in the physical stability of solid dosage formulations. J Pharm Sci, 94:2147–2165.
- Pyda M, Wunderlich B. (2005). Reversing and nonreversing heat capacity of poly(lactic acid) in the glass transition region by temperature-modulated differential scanning calorimetry. Macromolecules, 38:10472–10479.
- Craig DQ, Barsnes M, Royall PG, Kett VL. (2000). An evaluation of the use of modulated temperature DSC as a means of assessing the relaxation behaviour of amorphous lactose. Pharm Res, 17:696–700.